AU6446194A - Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof - Google Patents

Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Info

Publication number
AU6446194A
AU6446194A AU64461/94A AU6446194A AU6446194A AU 6446194 A AU6446194 A AU 6446194A AU 64461/94 A AU64461/94 A AU 64461/94A AU 6446194 A AU6446194 A AU 6446194A AU 6446194 A AU6446194 A AU 6446194A
Authority
AU
Australia
Prior art keywords
immunotoxins
growth factor
monoclonal antibodies
fibroblast growth
antibodies specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64461/94A
Inventor
J. Andrew Baird
Douglas A Lappi
Wenbin Ying
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whittier Institute for Diabetes and Endocrinology
Original Assignee
Whittier Institute for Diabetes and Endocrinology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whittier Institute for Diabetes and Endocrinology filed Critical Whittier Institute for Diabetes and Endocrinology
Publication of AU6446194A publication Critical patent/AU6446194A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU64461/94A 1993-03-17 1994-03-14 Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof Abandoned AU6446194A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US031429 1987-03-27
US3142993A 1993-03-17 1993-03-17
US19699594A 1994-02-14 1994-02-14
US196995 1994-02-14
PCT/US1994/002753 WO1994021813A1 (en) 1993-03-17 1994-03-14 Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Publications (1)

Publication Number Publication Date
AU6446194A true AU6446194A (en) 1994-10-11

Family

ID=26707232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64461/94A Abandoned AU6446194A (en) 1993-03-17 1994-03-14 Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Country Status (2)

Country Link
AU (1) AU6446194A (en)
WO (1) WO1994021813A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1342476A3 (en) * 1995-06-12 2003-09-17 Yeda Research And Development Co. Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours
GB0718045D0 (en) 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
SI3702371T1 (en) 2009-03-25 2023-01-31 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
US20150125445A1 (en) * 2012-06-13 2015-05-07 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for treating cancer
CN105246511A (en) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 Methods of treating and preventing cancer drug resistance
CN107073121A (en) 2014-06-13 2017-08-18 基因泰克公司 Treatment and the method for prevention cancer drug resistance
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
ES2091018T3 (en) * 1992-06-18 1996-10-16 Whittier Inst Diabetes & Endoc PROCEDURE FOR THE DETECTION OF NEOPLASTIC DISEASES.

Also Published As

Publication number Publication date
WO1994021813A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU5869596A (en) Anti-gp130 monoclonal antibodies
AU6267896A (en) Antibody and antibody fragments for inhibiting the growth oftumors
AU1704099A (en) Monoclonal human natural antibodies
PL314908A1 (en) Humanised antibodies and their application
IL128406A0 (en) Monoclonal antibodies
AU4618193A (en) Humanized antibodies
AU7041996A (en) Antibody specific for beta1->6N- acetylglucosamininyltransferase
AU5611394A (en) Antibodies for gm-csf receptor and uses thereof
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU3576797A (en) Anti-cocaine catalytic antibody
AU7081094A (en) Cell growth factor receptors
AU2645297A (en) Hepatitis b monoclonal antibodies
AU6446194A (en) Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
AU4256096A (en) Monoclonal antibody fragments having immunosuppressant activity
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
AU659873B2 (en) Human monoclonal antibody against glycoprotein IIb/IIIa
AU1796692A (en) Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
AU7014294A (en) Human monoclonal antibodies and processes and materials for making such antibodies
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
AU657504B2 (en) Antibody against human plasmin-alpha2-plasmin inhibitor complex, hybridoma and immunoassay
AU7504691A (en) Monoclonal antibodies against pp4, processes for the preapration thereof and the use thereof
AU8547291A (en) Monoclonal antibodies against tenascin
AU3079895A (en) Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies